fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Theophylline anhydrous

All products: general benefit

Theo ER · DIN 02360101 · 400 mg · extended release tablet

General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Theo ER · DIN 02360101 Manufacturer: A A Pharma Inc.; listing date 2014-01-03 Health Canada: Marketed since 2011-06-23 · brand THEO ER · ATC R03DA04 THEOPHYLLINE · form Tablet (extended-release) · route Oral · ingredients THEOPHYLLINE 400 MG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ministry pays: $0.3734 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02360101)

Source record
DIN 02360101: Theo ER Raw flags: sec3=Y Item: 860000046; group id 878; item number 2119; lccId None; manufacturer id AAP Source form: SR Tab; strength: 400mg Recorded listing: General benefit Source prices (unrounded): $0.3735; ministry $0.3734 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02360101 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84507
Interchangeable products
Uniphyl · DIN 02014165 · not recorded
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (R03DA): coverage varies; not interchangeable

  • Oxtriphylline (Choledyl): general benefit
Other drugs in the same formulary class (86:00 SPASMOLYTICS) and how they are covered

Matched class: 86:00 SPASMOLYTICS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: OXTRIPHYLLINE 86:00 SPASMOLYTICS

OXTRIPHYLLINE

· 1 products · General benefit · strengths: 20mg/mL · O/L

FESOTERODINE FUMARATE

· 6 products · Limited Use, codes 290 · strengths: 4mg, 8mg · Tab

MIRABEGRON

· 5 products · Limited Use, codes 290 · strengths: 25mg, 50mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 86:00 86:12:04 Antimuscarinics

PROPIVERINE HYDROCHLORIDE

· 1 products · Limited Use, codes 530 · strengths: 5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 86:12:04
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. INDICATIONS THEO ER (theophylline sustained release tablets) is indicated for: Symptomatic treatment of reversible bronchoconstriction associated with asthma, emphysema, chronic bronchitis and related bronchospastic disorders in patients 12 years and older. 1.1. Pediatrics Pediatrics (<12 years of age): THEO ER is not recommended for use in children under 12 years of age. 1.2. Geriatrics Geriatrics (>65 years of age): Dose Reduction may be required in elderly patients (see DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS) https://pdf.hres.ca/dpd_pm/00063080.PDF PM date: September 28, 2021 Source product: THEO ER; DIN 02360101; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.